Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the appointment of Philippe Brianceau, DVM, as chief veterinary officer, effective immediately.
Philippe Brianceau brings more than 20 years of animal health experience following the completion of his doctorate in veterinary medicine from the Toulouse Veterinary School in France. Most recently, Brianceau served as director of global pharmaceutical project development at Merck Animal Health, where he led new product development teams for both companion and livestock animals. He also served as director of US clinical research for Merck Animal Health for four years, during which time he oversaw field study operations and clinical development plans for new animal drugs. Brianceau began his career in the pharmaceutical industry in 2001 with Schering Plough Animal Health, followed by Intervet, where he remained through the organization's acquisition by Merck Pharmaceuticals in 2009.
"The addition of Dr. Brianceau to the Jaguar management team comes at a pivotal time for the Company, as we recently announced additional positive findings from our SB-300 proof-of-concept study for equine gastric ulcer syndrome," said Lisa Conte, Jaguar's president and CEO. "Philippe's research and development experience at Merck Animal Health in conjunction with his past experience in equine internal medicine and surgery will provide unparalleled insight into the equine and companion animal markets-two of our core focus areas. We are confident in his ability to lead our veterinary team as we pursue regulatory approvals and initiate further clinical trials and research activities."
Philippe Brianceau stated, "I am very excited to be named chief veterinary officer of an emerging animal health company committed to developing innovative, first-in-class products for both companion and production animals. I look forward to leveraging my experience in pharmaceutical product development and my background in veterinary medicine and surgery to help Jaguar bring the multiple products in its pipeline to market."
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is Jaguar's lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. SB-300 is Jaguar's prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and SB-300 contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company's lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of SB-300 in horses, and Canalevia™ for cats and dogs.
For more information, please visit www.jaguaranimalhealth.com .
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's intention to bring the multiple products in its pipeline to market, Jaguar's plans to develop species-specific formulations of Neonorm™ in additional target species, and the Company's plan to develop formulations of SB-300 in horses and formulations of Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.